OREANDA-NEWS. As more pharmaceutical companies outsource their clinical trials to contract research organizations (CROs), CROs are challenged to complete the clinical research in a more efficient and timely manner. Oracle Health Sciences today announced that Simbec-Orion Group Limited, a full service, international, boutique CRO, has adopted Oracle’s suite of eClinical cloud solutions to simplify the management of its customer’s clinical studies.

Oracle’s life sciences-specific solutions, combined with its broader product and service offering, are used by thousands of pharma, biopharma, and academic research centers worldwide to redesign clinical R&D processes, advance drug therapies, and optimize care delivery to improve the health, well-being, and lives of people globally.

Simbec-Orion Group selected cloud-based Oracle Health Sciences InForm, Siebel Oracle's Siebel Clinical Trial Management System, and Oracle Health Sciences IRT to supplement its clinical development processes, streamline data capture, and speed up trial timelines as Simbec-Orion expands its international, full-service, business offerings.

“We reviewed a wide range of providers to ensure, that as a world-class CRO, we were working with the best–in-class systems”, said Ronald Openshaw, CEO, Simbec-Orion. “We chose to partner with Oracle, the market leader in eClinical solutions, as we wanted to rely upon an excellent, secure, robust, and state-of-the-art service that will meet current and foreseeable, future, market needs.  We believe the scalability will drive efficiency in our work practices as we grow, especially in the light of increasingly complex clinical trials.”

“Oracle shares Simbec-Orion’s commitment to helping pharma and biotechnology companies deliver high-quality therapies to the patients we serve,” said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences. “ We look forward to working with Simbec-Orion as it further expands and enhances its clinical development services powered by our innovative technology.”

In 2014 through the merger of the two independent CROs, Simbec Research and Orion Clinical, Simbec-Orion Group was created as an international boutique CRO. Simbec-Orion Group now offers a full spectrum of drug development services from first-in-human Phase I clinical studies, through to pivotal Phase III studies and Phase IV post marketing studies. Starting in January 2016, unless the client expresses different requirements, new studies across the Simbec-Orion Group will use Oracle’s eClinical suite.